Epidemiological aspects of central serous chorioretinopathy

D R Agliullin; G R Khasanova; E A Abdulaeva; S T Agliullina; A N Amirov; A N Kuskov; A A Kim; A Yu Rascheskov; D A Lipinskiy

doi:10.17816/KMJ2021-228

Kazan medical journal ›› 2021, Vol. 102 ›› Issue (2) : 228 -233. DOI: 10.17816/KMJ2021-228

Social hygiene and healthcare management

research-article

Epidemiological aspects of central serous chorioretinopathy

Author information +

History +

PDF (399KB)

Abstract

Aim. To analyze the incidence of central serous chorioretinopathy among the Kazan’s population between 2009 and 2018.

Methods. A descriptive epidemiological study of the incidence of Central serous chorioretinopathy of the population of Kazan between 2009 and 2018 was conducted. It included an analysis of long-term changes in the incidence of male and female population and an assessment of the structure of morbidity by sex for the entire period and in dynamics. Testing for differences was performed using the nonparametric Mann–Whitney U test and Chi-square test with Yates correction.

Results. 831 new cases of central serous chorioretinopathy were registered in Kazan during 2009–2018, the ratio of men and women was approximately 1:1. In the dynamics of morbidity, the proportion of men increased from 24.2% in 2009 to 60.7% in 2018 (р=0.000002), while the proportion of women decreased from 75.8% in 2009 to 39.3% in 2018 (р=0.000002). The long-term dynamics for 2009–2018 is characterized by a statistically significant increase in the incidence rate of central serous chorioretinopathy in men (p=0.004) from 3.2 per 100 000 in 2009 to 14.8 per 100 000 in 2018. During the study period, the incidence rate in women remains at the same level, varying from 5.4 per 100 000 to 8 per 100 000 (p=0.663). Men are more likely to have central serous chorioretinopathy at a younger age (р=0.0001). The median age at the time of diagnosis in women was 55 years (Q25–Q75 45–65 years), in men — 45 years (Q25–Q75 37–56 years).

Conclusion. From 2009 to 2018, the incidence rate of central serous chorioretinopathy among men in Kazan significantly increased in both intensive (p=0.004) and extensive indicators (p=0.000002); сentral serous chorioretinopathy in men develops at an earlier age compared with women (median age of women at the time of diagnosis was 55 years, median age of men — 45 years, p=0.0001).

Keywords

central serous chorioretinopathy / epidemiology / retrospective analysis / incidence / structure by gender / age

Cite this article

Download citation ▾

D R Agliullin, G R Khasanova, E A Abdulaeva, S T Agliullina, A N Amirov, A N Kuskov, A A Kim, A Yu Rascheskov, D A Lipinskiy. Epidemiological aspects of central serous chorioretinopathy. Kazan medical journal, 2021, 102(2): 228-233 DOI:10.17816/KMJ2021-228

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Gemenetzi M., De Salvo G., Lotery A.J. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye (Lond.). 2010; 24 (12): 1743–1756. DOI: 10.1038/eye.2010.130.

[2]	Wang M., Munch I.C., Hasler P.W., Prunte C., Larsen M. Central serous chorioretinopathy. Acta Ophthalmol. 2008; 86 (2): 126–145. DOI: 10.1111/j.1600-0420.2007.00889.x.

[3]	Khasanova G.R., Hakimov N.M., Аgliullin D.R., Abdulaeva E.A. Risk factors for central serous chorioretinopathy. Systematic review and meta-analysis. Meditsina. 2020; 8 (1): 102–124. (In Russ.) DOI: 10.29234/2308-9113-2020-8-1-102-124.

[4]	Хасанова Г.Р., Хакимов Н.М., Аглиуллин Д.Р., Абдулаева Э.А. Факторы риска развития центральной серозной хориоретинопатии. Систематический обзор и метаанализ. Медицина. 2020; 8 (1): 102–124. DOI: 10.29234/2308-9113-2020-8-1-102-124.

[5]	Liew G., Quin G., Gillies M., Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin. Experim. Ophthalmol. 2013; 41: 201–214. DOI: 10.1111/j.1442-9071.2012.02848.x.

[6]	Kitzmann A.S., Pulido J.S., Diehl N.N., Hodge D.O., Burke J.P. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology. 2008; 115: 169–173. DOI: 10.1016/j.ophtha.2007.02.032.

[7]	Tsai D.C., Chen S.J., Huang C.C. Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001–2006: a population-based study. PLoS One. 2013; 8 (6): е66858. DOI: 10.1371/journal.pone.0066858.

[8]	Savilov Ye.D., Astaf'yev V.A., Zhdanova S.N., Zarudnev Ye.A. Epidemiologicheskiy analiz: metody statisticheskoy obrabotki materiala. (Epidemiological analysis: methods of statistical processing of the material.) Novosibirsk: Nauka-Tsentr. 2011; 156 p. (In Russ.)

[9]	Савилов Е.Д., Астафьев В.А., Жданова С.Н., Заруднев Е.А. Эпидемиологический анализ: методы статистической обработки материала. Новосибирск: Наука-Центр. 2011; 156 с.

[10]	Yildiz O., Seyrek M. Vasodilating mechanisms of testosterone. Exp. Clin. Endocrinol. Diabetes. 2007; 115 (1): 1–6. DOI: 10.1055/s-2007-949657.

[11]	Ahad M.A., Chua C.N., Evans N.M. Central serous chorioretinopathy associated with testosterone therapy. Eye. 2005; 20: 503–505. DOI: 10.1038/sj.eye.6701905.

[12]	Ciloglu E., Unal F., Dogan N.C. The relationship between the central serous chorioretinopathy, choroidal thickness, and serum hormone levels. Graefes Arch. Clin. Exp. Ophthalmol. 2018; 256 (6): 1111–1116. DOI: 10.1007/s00417-018-3985-x.

[13]	Haimovici R., Koh S., Gagnon D.R., Lehrfeld T., Wellik S. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology. 2004; 111: 244–249. DOI: 10.1016/j.ophtha.2003.09.024.

[14]	Chumbley L.C., Frank R.N. Central serous retinopathy and pregnancy. Am. J. Ophthalmol. 1974; 77 (2): 158–160. DOI: 10.1016/0002-9394(74)90667-9.

[15]	Morikawa M., Cho K., Kojima T., Chiba K., Ishikawa S., Umazume T., Nakagawa K., Yamada T., Yamada T., Minakami H. Risk factors for central serous chorioretinopathy in pregnant Japanese women. J. Obstet. Gynaecol. Res. 2017; 43 (5): 866–872. DOI: 10.1111/jog.13289.

[16]	Ersoz M.G., Arf S., Hocaoglu M., Sayman Muslubas I., Karacorlu M. Patient characteristics and risk factors for central serous chorioretinopathy: an analysis of 811 patients. Brit. J. Ophthalmol. 2019; 103 (6): 725–729. DOI: 10.1136/bjophthalmol-2018-312431.

[17]	Chatziralli I., Kabanarou S.A., Parikakis E., Chatzirallis A., Xirou T., Mitropoulos P. Risk factors for central serous chorioretinopathy: multivariate approach in a case-control study. Curr. Eye Res. 2017; 42 (7): 1069–1073. DOI: 10.1080/02713683.2016.1276196.

[18]	Conway M.D., Noble J.A., Peyman G.A. Central serous chorioretinopathy in postmenopausal women receiving exogenous testosterone. Retin. Cases Brief. Rep. 2017; 11 (2): 95–99. DOI: 10.1097/ICB.0000000000000298.

[19]

Аgliullin D.R., Khasanova G.R., Abdulaeva E.A., Agliullina S.T., Amirov A.N., Kuskov A.N., Kim A.A., Rascheskov A.Yu., Lipinskiy D.A. The incidence of central serous chorioretinopathy in the population of Kazan: Results of a retrospective epidemiological analysis for 2009–2018. Tikhookeanskiy meditsinskiy zhurnal. 2020; (3): 30–33. (In Russ.) DOI: 10.34215/1609-1175-2020-3-30-33.

[20]

Аглиуллин Д.Р., Хасанова Г.Р., Абдулаева Э.А., Аглиуллина С.Т., Амиров А.Н., Кусков А.Н., Ким А.А., Расчёсков А.Ю., Липинский Д.А. Заболеваемость центральной серозной хориоретинопатией населения г. Казани: результаты ретроспективного эпидемиологического анализа за 2009–2018 гг. Тихоокеанский мед. ж. 2020; (3): 30–33. DOI: 10.34215/1609-1175-2020-3-30-33.